Sveriges Riksbank
24.2.2026 09:30:00 CET | Globenewswire | Press release
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
| Bid date, 2026-02-24 | |
| Auction date | 2026-02-24 |
| Settlement date | 2026-02-25 |
| Maturity Date | 2026-03-04 |
| Nominal amount | 522 billion SEK |
| Interest rate | 1.75 % |
| Bid times | 09.30-10.00 (CET/CEST) on the Bid date |
| Bids are made to phone number | 08-696 69 70 |
| Confirmation of bids to e-mail | rbcert@riksbank.se |
| The lowest accepted bid volume | 1 million SEK |
| The highest accepted bid volume | 522 billion SEK |
| Allocation Time | 10.15 (CET/CEST) on the Bid date |
| Projected minimum liquidity surplus during the term | 522 billion SEK |
| Expected excess liquidity at full allotment | 0 billion SEK |
Stockholm, 2026-02-24
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
SERB Pharmaceuticals23.10.2026 21:01:27 CEST | Press release
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
F. Hoffmann-La Roche Ltd23.10.2026 19:30:00 CEST | Press release
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
TecDo Technology Co., Limited23.10.2026 18:37:22 CEST | Press release
TGC 2026: Tec-Do Launches Navos Pro for Results-Driven AI for Work
CGTN23.10.2026 18:17:10 CEST | Pressemeddelelse
CGTN: Hvad fortæller historien om 'Half a Quilt' (Et halvt vattæppe) os om Kinas nye lange march?
Genmab A/S23.10.2026 17:55:00 CEST | Press release
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom